CEO Insights Magazine

Aiming to bolster the US economy, President Donald Trump has introduced substantial reforms, particularly in foreign trade. One key measure includes imposing an additional 25 percent tariff on pharmaceutical imports. In the previous year, the US imported approximately 36 percent of its pharmaceutical products, totaling around $200 billion out of a $560 billion industry. Notably, Asian countries serve as major suppliers of generic pharmaceuticals to the US market. It needs to be seen how this decision will affect these dynamics, especially since Trump also mentioned that these pharma

companies would be given a chance to be exempted from tariffs by establishing facilities in the US.

The Philippines used to be one of the emerging exporters of Pharmaceutical products to the US in the previous years. However, in 2024, America imported only $6.08 million worth of pharmaceutical products from the Philippines—a significant decrease from the previous year, where pharmaceutical exports from the Philippines to the US clocked $37 million. In fact, the total value of pharmaceutical products exported from the Philippines last year only amounted to approximately $37 million, the lowest in more than a decade. However, the market within the country tells a whole different story. The Philippine pharmaceutical market is growing exponentially, with projections indicating it could reach $130 billion by 2030. Rising incomes, government backed healthcare initiatives, and increasing demand for cost effective medicines pilot the growth. Delving deep reveals that the market is hosting substantial expansion in sectors such as generic and biosimilar pharmaceuticals, active pharmaceutical ingredients, and pharmaceutical packaging.
Do let us know your thoughts.